Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
Applied Science Products operates Advanced Plasma Products, Inc., a science and en...
Applied Science Products operates Advanced Plas...
Alpine is a development-stage specialty pharmaceutical company focused on discover...
Alpine is a development-stage specialty pharmac...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the d...
Viking Therapeutics is a clinical-stage biophar...
Emisphere Technologies is a Drug Delivery Company whose core business strategy is ...
Emisphere Technologies is a Drug Delivery Compa...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pi...
Applied Therapeutics is a clinical-stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.